Structure via PubChem · Public domain (PubChem)
liraglutide
Sign in to saveAlso known as N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide, N²⁶-(N-hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide, Arg34Lys26-{N-ε-[γ-Glu(N-α-hexadecanoyl)]}-GLP-1[7-37]
Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type2 diabetes, and chronic obesity. It is a second-line therapy for diabetes following first-line therapy with metformin. Its effects on long-term health outcomes like heart disease and life expectancy are unclear. It is given by injection under the skin.
Key facts
- Drug.C
- 172
- Drug.H
- 265
- Drug.image
- Liraglutide cartoon 4APD.png
- Drug.image_class
- bg-transparent
- Drug.image2
- Liraglutide ball-and-stick 4APD.png
- Drug.image_class2
- bg-transparent
- Drug.caption
- NMR structure of liraglutide. PDB entry
- Drug.tradename
- Victoza, others
- Drug.MedlinePlus
- a611003
- Drug.DailyMedID
- Liraglutide
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- Subcutaneous
- Drug.ATC_prefix
- A10
- Drug.ATC_suffix
- BJ02
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C172H265N43O51
- Molecular weight
- 3751 g/mol
- IUPAC name
- (2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid
- SMILES
- CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CNC=N6)N)C(=O)O
- InChIKey
- YSDQQAXHVYUZIW-QCIJIYAXSA-N
- XLogP
- -3.4
- Polar surface area
- 1510 Ų
- H-bond donors
- 54
- H-bond acceptors
- 55
- Formal charge
- 0
via PubChem
Wikidata facts
- Mass
- 3749.949816
- Manufacturer
- Novo Nordisk
- Has use
- medication
Show 9 more facts
- chemical formula
- C₁₇₂H₂₆₅N₄₃O₅₁
- World Health Organisation international non-proprietary name
- liraglutide
- NCI Thesaurus ID
- C82239
- subject has role
- incretins
- medical condition treated
- glucose intolerance
- Commons category
- Liraglutide
- defined daily dose
- 1.5
- has characteristic
- biopharmaceutical
- legal status (medicine)
- boxed warning
Sources (6)
via Wikidata · CC0
~11 min read
Encyclopedic overview
16 sectionsContents
- Medical uses
- Type 2 diabetes
- Obesity
- Adverse effects
- Thyroid cancer
- Pancreatitis
- Suicidal behavior and ideation
- Pharmacodynamics
- Pharmacokinetics
- Society and culture
- Brand names
- Marketing
- Controversy
- History
- Research
- References
Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type2 diabetes, and chronic obesity. It is a second-line therapy for diabetes following first-line therapy with metformin. Its effects on long-term health outcomes like heart disease and life expectancy are unclear. It is given by injection under the skin.
Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics. It works by increasing insulin release from the pancreas and decreases excessive glucagon release.
Excerpted from Wikipedia’s “liraglutide” article, available under the CC BY-SA 4.0 licence.